A Simple Blood-Cell Index May Help Flag Heart Risk in Kawasaki Disease

Kawasaki disease remains the most common cause of acquired heart disease in children in much of the world, and the central question that haunts every clinician who treats it is deceptively simple: which child will develop a coronary artery aneurysm? A new commentary published in Pediatric Research by Khaled Saad of Assiut University and an international team of co-authors now turns the spotlight on a candidate answer drawn from the most routine of diagnostic tools, the complete blood count. The authors appraise the Aggregate Index of Systemic Inflammation, or AISI, a composite marker calculated from three standard hematological parameters, and argue that it may earn a place alongside established clinical and echocardiographic assessments as an additional signal of coronary risk. The commentary, published on 8 October 2026, is careful in its claims: the index may complement rather than replace existing tools, and prospective validation is required before it enters treatment decision pathways.

The biological problem the index addresses is the defining paradox of Kawasaki disease. The illness presents as a feverish, inflammatory condition of childhood, with mucocutaneous signs such as cracked lips, conjunctival injection, rash and swollen lymph nodes, yet its most consequential damage is vascular. In the acute phase, a diffuse inflammatory process targets the medium-sized arteries, and the coronary arteries are particularly vulnerable. When inflammation weakens the arterial wall, the vessel can dilate into an aneurysm, a lesion that may regress over time or persist for life, setting the stage for stenosis, thrombosis and ischemic heart disease decades later. Intravenous immunoglobulin, given within the first ten days of illness, dramatically reduces this risk, but a meaningful fraction of children still develop coronary abnormalities, and some fail to respond to first-line therapy at all. Identifying those children early, ideally at the first encounter, is the goal of every risk-stratification effort in the field.

Current practice relies on a patchwork of tools. The American Heart Association, in its 2024 scientific statement on the diagnosis and management of Kawasaki disease, emphasizes echocardiographic surveillance and clinical judgment, and standardized Z-score formulas are used to express a child’s coronary artery dimensions relative to body surface area, allowing clinicians to distinguish dilation from aneurysm and to track progression. Predictive models have also been developed, including a widely discussed risk model validated in a North American population by Son and colleagues, which combines demographic and laboratory variables to estimate aneurysm probability before treatment begins. Saad and colleagues themselves have contributed to this effort, publishing a predictive modeling approach for early risk stratification in Pediatric Research earlier in 2026. Yet each tool has limitations: models built in one population may not transfer to another, Z-scores depend on accurate imaging and appropriate formula selection, and no single laboratory value has proven sufficiently discriminating on its own.

Into this gap steps the Aggregate Index of Systemic Inflammation. The AISI belongs to a family of composite inflammatory cell indexes that have attracted growing attention across medicine because they can be derived at no additional cost from parameters already reported on every differential blood count. In its standard formulation, the index multiplies the platelet count, the neutrophil count and the monocyte count, and divides by the lymphocyte count. Each component captures a facet of the inflammatory response: neutrophils and monocytes are the cellular vanguard of innate inflammation, platelets are acute-phase reactants whose numbers climb as interleukin-6 drives thrombopoiesis, and lymphocytes tend to fall under the suppressive weight of stress hormones and inflammatory cytokines. A high AISI therefore reflects a convergence of myeloid activation, thrombocytosis and relative lymphopenia, a pattern that in many diseases tracks the intensity of systemic inflammation more faithfully than any single cell line.

The appeal of such an index in Kawasaki disease is grounded in the disease’s own biology. Recent reviews, including a 2024 analysis in Nature Reviews Rheumatology by Noval Rivas and colleagues, have highlighted platelets not as passive bystanders but as active mediators of vascular inflammation in the illness. Platelets interact directly with activated endothelium, release pro-inflammatory and pro-thrombotic mediators, and contribute to the remodeling of the vessel wall that underlies aneurysm formation. Neutrophils, meanwhile, have been implicated in endothelial injury through the release of neutrophil extracellular traps, and monocytes infiltrate the inflamed arterial wall. The idea that a product of these very cell counts might correlate with coronary outcomes is therefore not a statistical accident in search of a mechanism; it is a hypothesis with a plausible pathophysiological backbone. The same logic has propelled AISI research in adult cardiovascular medicine, where a 2024 retrospective study in the Journal of Inflammation Research reported associations between the index and clinical outcomes in patients with acute myocardial infarction.

The immediate trigger for the commentary is a study by Liu, Peng and Zhou, published online in Pediatric Research in September 2026, which examined the association between the AISI and coronary artery aneurysm in patients with Kawasaki disease. That investigation reported that a higher AISI was associated with the presence of coronary artery aneurysm, suggesting that the index could help identify children who require closer coronary surveillance. Saad and his co-authors, writing from institutions spanning Egypt, Jordan, Russia, Saudi Arabia, the United Kingdom and Pakistan, use their commentary to appraise what this finding means for practice. Their assessment, summarized in the article’s impact statements, is measured: the AISI may serve as an additional inflammatory marker for identifying children with Kawasaki disease who need closer coronary monitoring, and AISI-based risk stratification may ultimately contribute to personalized approaches in disease management.

The commentary’s caution is as instructive as its enthusiasm. The authors state plainly that current evidence supports further prospective validation before the AISI can be included in treatment decision pathways. This is a crucial distinction in pediatric cardiology, where treatment intensification, such as the addition of corticosteroids or other adjunctive agents for high-risk children, carries its own risks and where misclassifying a low-risk child as high-risk can expose an infant to unnecessary immunosuppression. A retrospective association, however biologically plausible, does not establish that the index adds predictive information beyond what is already captured by age, sex, days of fever at diagnosis, baseline laboratory values and serial echocardiography. Establishing incremental value requires prospective cohorts, ideally across multiple populations, in which the AISI is measured at diagnosis and tested against coronary outcomes in models that already include established predictors.

Several technical considerations will shape that validation. The AISI’s components are not static: platelet counts in Kawasaki disease typically rise in the second week of illness, so the timing of the blood draw relative to fever onset materially changes the value. Thrombocytosis may be absent in the first days, precisely when treatment decisions must be made, which raises the question of whether an early AISI retains discriminative power. Related composite indexes built from the same count, such as ratios pairing platelets, neutrophils or monocytes with lymphocytes, have been studied in other inflammatory and surgical settings, and head-to-head comparisons would clarify whether the full four-component product offers genuine added sensitivity. Albumin, a negative acute-phase reactant that has been linked to coronary lesion progression in retrospective cohorts, and other conventional markers such as C-reactive protein, provide further benchmarks against which any new index must prove itself. Standardization of cutoffs, which vary across studies and populations, is another unresolved hurdle.

The broader significance of the commentary lies in its vision of low-cost, widely accessible risk stratification. The complete blood count is among the cheapest and most universally available tests in medicine, including in the low- and middle-income settings where Kawasaki disease is often diagnosed late and where advanced imaging may be scarce. An index that extracts additional prognostic information from data already in hand, without new reagents, equipment or expense, aligns squarely with the needs of global pediatric practice. If prospective studies confirm that the AISI meaningfully refines aneurysm risk prediction, it could be incorporated into the early triage of children at diagnosis, flagging those who warrant intensified anti-inflammatory therapy, more frequent echocardiography or referral to specialized centers. Conversely, if validation fails, the episode will still have sharpened the field’s understanding of how cellular inflammation relates to coronary pathology.

For now, the message from Saad and colleagues is one of disciplined optimism. The Aggregate Index of Systemic Inflammation is not a new test but a new lens on an old one, and its candidacy in Kawasaki disease rests on a coherent mechanistic rationale and an emerging body of evidence rather than on settled proof. The authors declare no competing interests and received no external funding for the commentary, and they frame the index explicitly as a potential complement to, not a substitute for, established clinical and echocardiographic assessment. Children with Kawasaki disease will continue to be managed according to current guidelines, with intravenous immunoglobulin, aspirin and serial coronary imaging. But the commentary signals that the next chapter of aneurysm risk prediction may be written not with expensive biomarkers or novel imaging, but with a few numbers multiplied together from a blood count that every febrile child already receives.

Subject of Research: Evaluation of the Aggregate Index of Systemic Inflammation as a marker of coronary aneurysm risk in Kawasaki disease

Article Title: Inflammatory burden and coronary aneurysm risk in Kawasaki disease: appraising the Aggregate Index of Systemic Inflammation

Article References: Saad, K., Aly, S. E., Zeid, S. S. K., Ahmad, A. R., Elfarargy, M. S., Elkossi, M., Mumtaz, M. H., & Temsah, M.-H. (2026). Inflammatory burden and coronary aneurysm risk in Kawasaki disease: appraising the Aggregate Index of Systemic Inflammation. Pediatric Research. https://doi.org/10.1038/s41390-026-05590-4

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05590-4

Keywords: Kawasaki disease, coronary artery aneurysm, Aggregate Index of Systemic Inflammation, AISI, inflammation, pediatric cardiology, risk stratification, complete blood count, platelets, echocardiography, intravenous immunoglobulin, biomarkers